Key Insights

Highlights

Success Rate

89% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

5.6%

2 terminated out of 36 trials

Success Rate

88.9%

+2.3% vs benchmark

Late-Stage Pipeline

11%

4 trials in Phase 3/4

Results Transparency

25%

4 of 16 completed with results

Key Signals

4 with results89% success

Data Visualizations

Phase Distribution

26Total
Not Applicable (9)
P 1 (3)
P 2 (10)
P 3 (3)
P 4 (1)

Trial Status

Completed16
Unknown9
Recruiting5
Withdrawn3
Terminated2
Active Not Recruiting1

Trial Success Rate

88.9%

Benchmark: 86.6%

Based on 16 completed trials

Clinical Trials (36)

Showing 20 of 20 trials
NCT06176079Completed

Hyperpolarized Pyruvate (13C) Magnetic Resonance Imaging In Patients With Fatty Liver Disease

NCT07099118Phase 1RecruitingPrimary

A Safety, Tolerability, Pharmacokinetics/Pharmacodynamics Study of HEC169584 Capsules in Healthy Subjects

NCT04669158Phase 1CompletedPrimary

Study of Oral Idebenone to Treat Non-Alcoholic Steatohepatitis

NCT05357352Completed

Effect of Patient Demographics, Comorbidities, and Medications on Severity of NASH Fibrosis

NCT05463796Recruiting

InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer

NCT05574036Phase 2Active Not RecruitingPrimary

Comparative Study Between Febuxostat Versus Vitamin E in Non-alcoholic Steatohepatitis Patients With Hyperuricemia

NCT05480696Phase 2Recruiting

Soluble Fibre Supplementation in NAFLD

NCT06676813Not ApplicableRecruitingPrimary

Effect of Alternate Day Fasting Over Standard Medical Management Alone to Reverse Non-alcoholic Steatohepatitis.

NCT03863574Phase 2CompletedPrimary

Saroglitazar Magnesium in the Treatment of Non-Alcoholic Steatohepatitis

NCT05821010Phase 2RecruitingPrimary

Synbiotics and Fecal Microbiota Transplantation to Treat Non-Alcoholic Steatohepatitis

NCT04573543Completed

The Role of Immune Semaphorins in NAFLD

NCT05942547Phase 3UnknownPrimary

the Efficacy and Safety of Diosmin on Non-diabetic Patients With Non-alcoholic Steatohepatitis.

NCT03142867Terminated

The Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) in Adults

NCT03524365Not ApplicableCompletedPrimary

Bariatric Surgery Versus Non-alcoholic Steato-hepatitis

NCT05605158Phase 3UnknownPrimary

Comparative Clinical Study Between Empagliflozin Versus Pioglitazone in Non-diabetic Patients With Non-alcoholic Steatohepatitis

NCT05301231Unknown

Omics-based Predictors of NAFLD/Potential NASH

NCT03803540Phase 1Unknown

Fecal Microbiota Transplantation for the Treatment of Non-Alcoholic Steatohepatitis

NCT03883607Phase 2TerminatedPrimary

Elafibranor, PK and Safety in Children and Adolescents 8 to 17 Years of Age With Non Alcoholic Steatohepatitis (NASH)

NCT03432377CompletedPrimary

Coffee Consumption and NASH in the French Population.

NCT04571957CompletedPrimary

Expanding Donor Pool for Live Donor Liver Transplantation: Utilization of Donors With NASH After Optimization

Scroll to load more

Research Network

Activity Timeline